ClinicalTrials.gg
RecruitingNCT06399666IERVUpdated Sep 19, 2024

Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation

An observational study in Atrial Fibrillation, Inflammation and Genetic Predisposition to Disease, sponsored by Vrinnevi Hospital. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Vrinnevi Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
182
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Atrial Fibrillation with a site in Sweden — 24 open to participants now, 36 under way, 5 of them phase 3. Atrial Fibrillation · Sweden.

Planned enrollment
30th of 39
182 · median 480
Started
2023
with 6 others
Observational
40 of 135
4 open now
Primary completion
2025-06
later than 6 of 35 live
Registered
123rd of 135
by date

Among the 135 studies in Atrial Fibrillation with a site in Sweden, this one is the 30th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2023, is one of 40 observational ones, reaches primary completion later than 6 of the 35 other live ones, and was the 123rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

24 of the 135 studies in Atrial Fibrillation with a site in Sweden are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Atrial Fibrillation with a site in Sweden, or all of them as a file.
02

Study summary

Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value.

This prospective cohort study is planning to include 182 patients with persistent atrial fibrillation, planned for electrical cardioversion, and \>18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG.

An interim analysis will be conducted after more than 80 patients have been included. If the results from univariate and/or multivariable logistic regression on inflammatory markers and genetic expression regarding atrial fibrillation recurrence are significant, the study will be concluded.

03

Conditions studied

  • Atrial Fibrillation
  • Inflammation
  • Genetic Predisposition to Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study included patients aged 18 or older diagnosed with persistent atrial fibrillation (ICD-10 I48.1) scheduled for ECV. Inclusion took place from 2023-10-18 to 2025-06-01.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persistent atrial fibrillation (ICD-10 I48.1)
  • Age over 18 years

Exclusion criteria

Exclusion Criteria:

  • disease
  • Inflammatory diseases
  • Acute or chronic liver dysfunction
  • Ongoing infectious diseases
  • Thyroid disorders
  • Any other conditions known to impact inflammatory activity (including medication use and hematological diseases)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
182 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Prospective cohort

    Prospective cohort measuring the previously described biomarkers.

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    Blood sampling

06

What researchers measure

Primary outcomes

  1. Recurrence of AF

    Recurrence of atrial fibrillation or atrial flutter recorded on 12-lead ECG or through pacemaker interpretation

    Time frame: During follow-up (post ECV, day 7, 30, 90, and 180)

Secondary outcomes

  1. Fluctuations of biomarkers and gene expression during follow-up

    Change in biomarker level or expression of gene expressions during follow-up.

    Time frame: During follow-up (post ECV, day 7, 30, 90, and 180)

07

Study locations

2 of 2 sites recruiting
  • Medical department
    Jönköping, Småland, Sweden
    Recruiting
  • Cardiology Clinic
    Norrköping, Östergötland, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jun 2025, 19 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 19 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 6, 2024
StartActual
Oct 30, 2023
Primary completionEst.
Jun 1, 2025
CompletionEst.
Feb 28, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06399666
Lead sponsor
Vrinnevi Hospital
Collaborators
Ryhov County Hospital
Responsible party
Jakob Hytting (MD, Department of Cardiology, Principal Investigator, Doctoral Candidate, Vrinnevi Hospital) — Principal investigator
First posted
May 6, 2024
Start date
Oct 30, 2023
Primary completion
Jun 1, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Jakob Hytting, MD
Contact
jakob.hytting@liu.se
+46 + 707679724

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion